메뉴 건너뛰기




Volumn 25, Issue 11, 2003, Pages 2669-2708

Zoledronic Acid: A New Parenteral Bisphosphonate

Author keywords

Bisphosphonates; Bone metastases; Hypercalcemia; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; IBANDRONIC ACID; LOOP DIURETIC AGENT; NEW DRUG; PAMIDRONIC ACID; RINGER LACTATE SOLUTION; RISEDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

EID: 0344664559     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80327-2     Document Type: Article
Times cited : (104)

References (62)
  • 1
    • 0034062815 scopus 로고    scopus 로고
    • American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
    • American Society of Clinical Oncology Bisphosphonates Expert Panel
    • Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18:1378-1391.
    • (2000) J Clin Oncol , vol.18 , pp. 1378-1391
    • Hillner, B.E.1    Ingle, J.N.2    Berenson, J.R.3
  • 2
    • 0025329232 scopus 로고
    • Overview of cancer-related hypercalcemia: Epidemiology and etiology
    • Muggia FM. Overview of cancer-related hypercalcemia: Epidemiology and etiology. Semin Oncol. 1990;17(Suppl 5):3-9.
    • (1990) Semin Oncol , vol.17 , Issue.5 SUPPL. , pp. 3-9
    • Muggia, F.M.1
  • 3
    • 0041152833 scopus 로고    scopus 로고
    • Metastatic cancer to the bone
    • De Vita VT, Hellman S, Rosenberg SA, eds. Philadelphia, Pa: Lippincott Williams & Wilkins
    • Brown HK, Healy JH. Metastatic cancer to the bone. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:2713-2729.
    • (2001) Cancer: Principles and Practice of Oncology. 6th Ed. , pp. 2713-2729
    • Brown, H.K.1    Healy, J.H.2
  • 4
    • 0025969367 scopus 로고
    • Bone metastasis: Pathophysiology and management policy
    • Nielson OS, Munro AJ, Tannock IF. Bone metastasis: Pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
    • (1991) J Clin Oncol , vol.9 , pp. 509-524
    • Nielson, O.S.1    Munro, A.J.2    Tannock, I.F.3
  • 5
    • 0036729485 scopus 로고    scopus 로고
    • American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
    • Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.
    • (2002) J Clin Oncol , vol.20 , pp. 3719-3736
    • Berenson, J.R.1    Hillner, B.E.2    Kyle, R.A.3
  • 6
    • 0344024906 scopus 로고    scopus 로고
    • East Hanover, NJ: Novartis Pharmaceuticals Corporation
    • Zometa® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003.
    • (2003) Zometa® [Package Insert]
  • 7
    • 0034986001 scopus 로고    scopus 로고
    • Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies
    • Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol. 2001;28(Suppl 6):4-10.
    • (2001) Semin Oncol , vol.28 , Issue.6 SUPPL. , pp. 4-10
    • Green, J.R.1
  • 8
    • 0037103322 scopus 로고    scopus 로고
    • Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)
    • Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem. 2002;45:3721-3738.
    • (2002) J Med Chem , vol.45 , pp. 3721-3738
    • Widler, L.1    Jaeggi, K.A.2    Glatt, M.3
  • 9
    • 0033930168 scopus 로고    scopus 로고
    • Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
    • Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15:1467-1476.
    • (2000) J Bone Miner Res , vol.15 , pp. 1467-1476
    • Coxon, F.P.1    Helfrich, M.H.2    Van't Hof, R.3
  • 10
    • 0035051719 scopus 로고    scopus 로고
    • Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
    • Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28:465-473.
    • (2001) Bone , vol.28 , pp. 465-473
    • Benford, H.L.1    McGowan, N.W.2    Helfrich, M.H.3
  • 11
    • 0035146537 scopus 로고    scopus 로고
    • Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
    • Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242.
    • (2001) J Pharmacol Exp Ther , vol.296 , pp. 235-242
    • Dunford, J.E.1    Thompson, K.2    Coxon, F.P.3
  • 12
    • 0034214362 scopus 로고    scopus 로고
    • Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
    • Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949-2954.
    • (2000) Cancer Res , vol.60 , pp. 2949-2954
    • Boissier, S.1    Ferreras, M.2    Peyruchaud, O.3
  • 13
    • 0035866791 scopus 로고    scopus 로고
    • Bisphosphonate treatment inhibits the growth of prostate cancer cells
    • Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61:2602-2608.
    • (2001) Cancer Res , vol.61 , pp. 2602-2608
    • Lee, M.V.1    Fong, E.M.2    Singer, F.R.3    Guenette, R.S.4
  • 14
    • 0003255113 scopus 로고    scopus 로고
    • Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor
    • Abstract 1827
    • Witters L, Crispino J, Javeed M, et al. Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor. Proc Am Soc Clin Oncol. 2002;21:5b. Abstract 1827.
    • (2002) Proc Am Soc Clin Oncol , vol.21
    • Witters, L.1    Crispino, J.2    Javeed, M.3
  • 15
    • 0033783227 scopus 로고    scopus 로고
    • Bisphosphonates induce breast cancer cell death in vitro
    • Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000;15:2211-2221.
    • (2000) J Bone Miner Res , vol.15 , pp. 2211-2221
    • Fromigue, O.1    Lagneaux, L.2    Body, J.J.3
  • 16
    • 0034980406 scopus 로고    scopus 로고
    • Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment
    • Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin Oncol. 2001;28(Suppl 6):35-44.
    • (2001) Semin Oncol , vol.28 , Issue.6 SUPPL. , pp. 35-44
    • Mundy, G.R.1    Yoneda, T.2    Hiraga, T.3
  • 17
    • 0012298785 scopus 로고    scopus 로고
    • Zoledronate induces apoptosis of breast cancer cells in vitro - Evidence for additive and synergistic effects with taxol and tamoxifen
    • Abstract 2619
    • Jagdev SP, Croucher PI, Coleman RE. Zoledronate induces apoptosis of breast cancer cells in vitro - evidence for additive and synergistic effects with taxol and tamoxifen. Proc Am Soc Clin Oncol. 2000;20:664a. Abstract 2619.
    • (2000) Proc Am Soc Clin Oncol , vol.20
    • Jagdev, S.P.1    Croucher, P.I.2    Coleman, R.E.3
  • 18
    • 0035917560 scopus 로고    scopus 로고
    • The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel
    • Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer. 2001;84:1126-1134.
    • (2001) Br J Cancer , vol.84 , pp. 1126-1134
    • Jagdev, S.P.1    Coleman, R.E.2    Shipman, C.M.3
  • 19
    • 0033397214 scopus 로고    scopus 로고
    • Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
    • Derenne S, Amiot M, Barillé S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999;14:2048-2056.
    • (1999) J Bone Miner Res , vol.14 , pp. 2048-2056
    • Derenne, S.1    Amiot, M.2    Barillé, S.3
  • 20
    • 0034055664 scopus 로고    scopus 로고
    • Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
    • Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia. 2000;14:841-844.
    • (2000) Leukemia , vol.14 , pp. 841-844
    • Tassone, P.1    Forciniti, S.2    Galea, E.3
  • 21
    • 0037236978 scopus 로고    scopus 로고
    • Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer
    • Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9:295-306.
    • (2003) Clin Cancer Res , vol.9 , pp. 295-306
    • Corey, E.1    Brown, L.G.2    Quinn, J.E.3
  • 22
    • 0036791075 scopus 로고    scopus 로고
    • Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model
    • Lee YP, Schwarz EM, Davies M, et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 2002;62:5564-5570.
    • (2002) Cancer Res , vol.62 , pp. 5564-5570
    • Lee, Y.P.1    Schwarz, E.M.2    Davies, M.3
  • 23
    • 6844252283 scopus 로고    scopus 로고
    • Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
    • Myeloma Aredia Study Group
    • Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
    • (1998) J Clin Oncol , vol.16 , pp. 593-602
    • Berenson, J.R.1    Lichtenstein, A.2    Porter, L.3
  • 24
    • 0034937438 scopus 로고    scopus 로고
    • Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
    • McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035-1043.
    • (2001) Br J Haematol , vol.113 , pp. 1035-1043
    • McCloskey, E.V.1    Dunn, J.A.2    Kanis, J.A.3
  • 25
    • 0036721078 scopus 로고    scopus 로고
    • Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid
    • Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055-1061.
    • (2002) J Pharmacol Exp Ther , vol.302 , pp. 1055-1061
    • Wood, J.1    Bonjean, K.2    Ruetz, S.3
  • 26
    • 0034326253 scopus 로고    scopus 로고
    • Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts
    • Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60:6001-6007.
    • (2000) Cancer Res , vol.60 , pp. 6001-6007
    • Reinholz, G.G.1    Getz, B.2    Pederson, L.3
  • 27
    • 0042769110 scopus 로고    scopus 로고
    • Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats
    • Hornby SB, Evans GP, Hornby SL, et al. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int. 2003;72:519-527.
    • (2003) Calcif Tissue Int , vol.72 , pp. 519-527
    • Hornby, S.B.1    Evans, G.P.2    Hornby, S.L.3
  • 28
    • 0031754524 scopus 로고    scopus 로고
    • Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys
    • Binkley N, Kimmel D, Brunner J, et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res. 1998;13:1775-1782.
    • (1998) J Bone Miner Res , vol.13 , pp. 1775-1782
    • Binkley, N.1    Kimmel, D.2    Brunner, J.3
  • 29
    • 0031977199 scopus 로고    scopus 로고
    • Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
    • Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581-589.
    • (1998) J Bone Miner Res , vol.13 , pp. 581-589
    • Luckman, S.P.1    Hughes, D.E.2    Coxon, F.P.3
  • 30
    • 18644373689 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
    • Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42:1228-1236.
    • (2002) J Clin Pharmacol , vol.42 , pp. 1228-1236
    • Chen, T.1    Berenson, J.2    Vescio, R.3
  • 31
    • 0003263760 scopus 로고    scopus 로고
    • Population pharmacokinetics (PK) of Zometa
    • Abstract 814
    • Berenson JR, Ravera C, Ma P, et al. Population pharmacokinetics (PK) of Zometa. Proc Am Soc Clin Oncol. 2000;20:209a. Abstract 814.
    • (2000) Proc Am Soc Clin Oncol , vol.20
    • Berenson, J.R.1    Ravera, C.2    Ma, P.3
  • 32
    • 0347708657 scopus 로고    scopus 로고
    • The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal dysfunction
    • Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal dysfunction. J Clin Pharmacol. 2003;43:154-162.
    • (2003) J Clin Pharmacol , vol.43 , pp. 154-162
    • Skerjanec, A.1    Berenson, J.2    Hsu, C.3
  • 33
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 34
    • 0032880063 scopus 로고    scopus 로고
    • A dose-finding study of zoledronate in hypercalcemic cancer patients
    • Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res. 1999;14:1557-1561.
    • (1999) J Bone Miner Res , vol.14 , pp. 1557-1561
    • Body, J.J.1    Lortholary, A.2    Romieu, G.3
  • 35
    • 0035863508 scopus 로고    scopus 로고
    • Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
    • Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
    • (2001) J Clin Oncol , vol.19 , pp. 558-567
    • Major, P.1    Lortholary, A.2    Hon, J.3
  • 36
    • 0142092856 scopus 로고    scopus 로고
    • Phase I study of high dose calcitriol (1,25(OH)2 vitamin D3) and zoledronic acid in patients with prostate cancer
    • Abstract 777
    • Solit DB, Smaletz O, DeLaCruz A, et al. Phase I study of high dose calcitriol (1,25(OH)2 vitamin D3) and zoledronic acid in patients with prostate cancer. Proc Am Soc Clin Oncol. 2002;21:195a. Abstract 777.
    • (2002) Proc Am Soc Clin Oncol , vol.21
    • Solit, D.B.1    Smaletz, O.2    DeLaCruz, A.3
  • 37
    • 0034906503 scopus 로고    scopus 로고
    • A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
    • Berenson JR, Vescio RA, Rosen LS, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001;7:478-485.
    • (2001) Clin Cancer Res , vol.7 , pp. 478-485
    • Berenson, J.R.1    Vescio, R.A.2    Rosen, L.S.3
  • 38
    • 0035174823 scopus 로고    scopus 로고
    • A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
    • Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 2001;91:144-154.
    • (2001) Cancer , vol.91 , pp. 144-154
    • Berenson, J.R.1    Vescio, R.2    Henick, K.3
  • 39
    • 0035312469 scopus 로고    scopus 로고
    • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
    • Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-1200.
    • (2001) Cancer , vol.91 , pp. 1191-1200
    • Berenson, J.R.1    Rosen, L.S.2    Howell, A.3
  • 40
    • 0035463593 scopus 로고    scopus 로고
    • Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
    • Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
    • (2001) Cancer J , vol.7 , pp. 377-387
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3
  • 41
    • 0037009822 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    • Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1458-1468
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 42
    • 10744229392 scopus 로고    scopus 로고
    • Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases
    • Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9:2394-2399.
    • (2003) Clin Cancer Res , vol.9 , pp. 2394-2399
    • Ibrahim, A.1    Scher, N.2    Williams, G.3
  • 43
    • 0042914647 scopus 로고    scopus 로고
    • Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    • Rosen LS, Gordon G, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-3157.
    • (2003) J Clin Oncol , vol.21 , pp. 3150-3157
    • Rosen, L.S.1    Gordon, G.2    Tchekmedyian, S.3
  • 44
    • 9044219839 scopus 로고    scopus 로고
    • Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
    • Myeloma Aredia Study Group
    • Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.
    • (1996) N Engl J Med , vol.334 , pp. 488-493
    • Berenson, J.R.1    Lichtenstein, A.2    Porter, L.3
  • 45
    • 0016804136 scopus 로고
    • A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
    • Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
    • (1975) Cancer , vol.36 , pp. 842-854
    • Durie, B.G.1    Salmon, S.E.2
  • 46
    • 0027407786 scopus 로고
    • The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
    • Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
    • (1993) J Clin Oncol , vol.11 , pp. 570-579
    • Cella, D.F.1    Tulsky, D.S.2    Gray, G.3
  • 47
    • 0025688231 scopus 로고
    • EuroQol - A new facility for the measurement of health-related quality of life
    • The EuroQol Group
    • EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199-208.
    • (1990) Health Policy , vol.16 , pp. 199-208
  • 48
    • 0036899876 scopus 로고    scopus 로고
    • Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain
    • Walker K, Medhurst SJ, Kidd BL, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain. 2002;100:219-229.
    • (2002) Pain , vol.100 , pp. 219-229
    • Walker, K.1    Medhurst, S.J.2    Kidd, B.L.3
  • 49
    • 0037186926 scopus 로고    scopus 로고
    • Intravenous zoledronic acid in postmenopausal women with low bone mineral density
    • Reid IR, Borwn JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
    • (2002) N Engl J Med , vol.346 , pp. 653-661
    • Reid, I.R.1    Borwn, J.P.2    Burckhardt, P.3
  • 50
    • 0036606093 scopus 로고    scopus 로고
    • Diagnosis of osteoporosis and assessment of fracture risk
    • Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-1936.
    • (2002) Lancet , vol.359 , pp. 1929-1936
    • Kanis, J.A.1
  • 51
    • 0038075478 scopus 로고    scopus 로고
    • Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer
    • Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol. 2003;169;2008-2012.
    • (2003) J Urol , vol.169 , pp. 2008-2012
    • Smith, M.R.1    Eastham, J.2    Gleason, D.M.3
  • 52
    • 10744233248 scopus 로고    scopus 로고
    • Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation
    • Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003;63:1130-1136.
    • (2003) Kidney Int , vol.63 , pp. 1130-1136
    • Haas, M.1    Leko-Mohr, Z.2    Roschger, P.3
  • 53
    • 0038657557 scopus 로고    scopus 로고
    • Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis
    • Matsuo A, Shuto T, Hirata G, et al. Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol. 2003;30:1280-1290.
    • (2003) J Rheumatol , vol.30 , pp. 1280-1290
    • Matsuo, A.1    Shuto, T.2    Hirata, G.3
  • 54
    • 0036187721 scopus 로고    scopus 로고
    • The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage
    • Muehleman C, Green J, Williams JM, et al. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage. 2002;10:226-233.
    • (2002) Osteoarthritis Cartilage , vol.10 , pp. 226-233
    • Muehleman, C.1    Green, J.2    Williams, J.M.3
  • 55
    • 0035049894 scopus 로고    scopus 로고
    • The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone
    • Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone. 2001;28:461-464.
    • (2001) Bone , vol.28 , pp. 461-464
    • Garnero, P.1    Christgau, S.2    Delmas, P.D.3
  • 56
    • 0031886744 scopus 로고    scopus 로고
    • Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease
    • Garnero P, Gineyts E, Schaffer AV, et al. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. 1998;41:354-360.
    • (1998) Arthritis Rheum , vol.41 , pp. 354-360
    • Garnero, P.1    Gineyts, E.2    Schaffer, A.V.3
  • 57
    • 0030896159 scopus 로고    scopus 로고
    • Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone
    • Arden-Cordone M, Siris ES, Lyles KW et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int. 1997;60:415-418.
    • (1997) Calcif Tissue Int , vol.60 , pp. 415-418
    • Arden-Cordone, M.1    Siris, E.S.2    Lyles, K.W.3
  • 58
    • 18844467280 scopus 로고    scopus 로고
    • Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study
    • Buckler H, Fraser W, Hosking D, et al. Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study. Bone. 1999;24(Suppl 5):81S-85S.
    • (1999) Bone , vol.24 , Issue.5 SUPPL.
    • Buckler, H.1    Fraser, W.2    Hosking, D.3
  • 59
    • 0035879143 scopus 로고    scopus 로고
    • Safety and efficacy of bisphosphonates beyond 24 months in cancer patients
    • Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001;19:3434-3437.
    • (2001) J Clin Oncol , vol.19 , pp. 3434-3437
    • Ali, S.M.1    Esteva, F.J.2    Hortobagyi, G.3
  • 60
    • 0034810866 scopus 로고    scopus 로고
    • A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease
    • DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001;9:545-551.
    • (2001) Support Care Cancer , vol.9 , pp. 545-551
    • DesHarnais Castel, L.1    Bajwa, K.2    Markle, J.P.3
  • 61
    • 0034660662 scopus 로고    scopus 로고
    • Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies
    • Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies. Cancer. 2000;88(Suppl 12):3080-3088.
    • (2000) Cancer , vol.88 , Issue.12 SUPPL. , pp. 3080-3088
    • Diel, I.J.1    Solomayer, E.F.2    Bastert, G.3
  • 62
    • 0034990442 scopus 로고    scopus 로고
    • Unmet needs in metastatic bone disease and its complications: Is progress possible?
    • Hortobagyi GN. Unmet needs in metastatic bone disease and its complications: Is progress possible? Semin Oncol. 2001;28(Suppl 6):1-3.
    • (2001) Semin Oncol , vol.28 , Issue.6 SUPPL. , pp. 1-3
    • Hortobagyi, G.N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.